Two consecutive quarters of revenue growth, a 6.3% Q4 beat above the top of guidance, and a 14% stock surge on earnings day tell you the turnaround at Herbalife is no longer speculative.
You can assess whether the $5 billion revenue base, the improving distributor trends in North America and Latin America, and the 2026 EBITDA guidance above consensus make this a worthwhile position now.
Market Impact (Sponsored)
Oil has moved above $100 a barrel as tensions in the Middle East continue to reshape expectations across global energy markets.
While daily headlines can drive sharp swings, the bigger story may be what higher crude prices mean for select energy companies with strong cash flow and operating leverage.
Zacks has outlined three oil stocks that may be well positioned if elevated prices persist.
Read the report.
Q4 Beat Every Guidance Metric and the Stock Responded Immediately
Herbalife Ltd. (NYSE: HLF) posted Q4 2025 net sales of $1.3 billion, up 6.3% year over year. That beat the top of its own guidance range of 1.5% to 5.5% and marked the strongest quarterly growth since Q2 2021.
Adjusted EBITDA came in at $156 million, also above guidance. The stock jumped 14% overnight. This was not a modest beat. It was a clean beat across every metric they guided to.
The second consecutive quarter of year-over-year growth is the part that matters more than any single number. One good quarter in a turnaround gets dismissed.
Two in a row starts changing the narrative. North America posted its second consecutive quarter of double-digit growth in new distributors, up 19% year over year.
Latin America delivered its seventh straight quarter of distributor growth. These are leading indicators that tell you the business is attracting new people, not just harvesting existing ones.
Q4 net sales up 6.3% to $1.3B: Beat the top of the 1.5% to 5.5% guidance range.
North America's new distributors up 19% year over year: Two straight quarters of double-digit distributor growth.
Adjusted EBITDA of $156M, above guidance: Second consecutive year of EBITDA margin expansion.
Full-year 2025 net sales were $5.04 billion, adjusted EBITDA was $658 million, and free cash flow margin improved to 6.2% from 3.6%. The business is generating more cash on less revenue growth.
Action: Buy HLF now and hold through the Q1 print. Exit if Q1 sales growth misses the 3% to 7% guidance range.
Big Opportunity (Sponsored)
As global tensions rise, one company is quietly supporting every branch of the U.S. military.
Army. Navy. Air Force. Marines.
That company is SpaceX.
But what most people don’t realize is that it may not stay private forever.
There’s growing speculation that Elon Musk could eventually bring it public in what could be one of the largest IPOs ever.
If that happens, early positioning could be critical.
Click here to see how some investors are preparing
India Hit a Record Quarter, and That Changes the Geographic Story
India delivered $250 million in Q4, up roughly 15% year over year, its highest quarterly sales in company history. That single market accounted for a meaningful portion of the Q4 outperformance.
Even stripping India out entirely, management said Q4 net sales would still have come in above the midpoint of guidance. India is adding to an already-beating business, not masking a weak one.
Latin America delivered its seventh consecutive quarter of growth. Asia Pacific and EMEA were both positive.
China was the one weak spot, down 6% in local currency, with recovery not expected until 2027. Price in that risk, but the rest of the portfolio is currently carrying it.
India Q4 net sales of $250M, up 15% year over year: Record quarter for the market.
China down 6% in local currency in Q4: Recovery not expected until 2027.
India is a high-growth wellness market where Herbalife has been investing in distributors for years. A record quarter is the output of that investment, not a one-off.
Action: If HLF pulls back to $16 to $17 on market weakness, add. India at a record and Latin America on a seven-quarter streak tells you this is not a one-region story.
Big Leap (Sponsored)
He revived EVs, revolutionized space, and built the biggest satellite network.
But this AI tech could go down in history as the crown jewel of Elon's career.
Nvidia CEO Jensen Huang says, "What Elon and his team has achieved is singular. It's never been done before."
Get the full story here.
The Balance Sheet Is the Best It Has Been in Years
Herbalife cut its total leverage ratio from 3.9x at the end of 2023 to 2.8x at the end of 2025. That 1.1 turn of deleveraging came from $283 million in debt repayment during 2025, funded by operating cash flow of $333 million.
The company is paying down real debt with real cash, not refinancing and extending.
This is meaningful because Herbalife's debt load had been a significant concern hanging over the stock for several years. At 2.8x leverage, that concern shrinks considerably.
Operating cash flow of $333 million on $5 billion in net sales is a 6.6% cash conversion rate, up from prior years.
Better working capital management and lower capex as a percentage of revenue are driving the improvement.
Leverage cut from 3.9x to 2.8x in two years: The debt overhang is shrinking.
Free cash flow margin improved to 6.2% from 3.6%: Cash generation is accelerating.
At 2.8x, HLF still carries meaningful debt, but two more years at this paydown pace gets leverage to approximately 1.5x, which is where the stock gets treated as a healthy business rather than a recovery trade.
Action: If leverage drops below 2.5x by Q2 2026, add aggressively. That is the re-rating trigger. If it stops declining or ticks back up, cut your position.
The 2026 Guidance Came In Above What Analysts Expected
For 2026, Herbalife guided net sales growth of 1% to 6% and EBITDA of $670 million to $710 million. The midpoint beats analyst projections.
Q1 guidance of 3% to 7% sales growth with $155 million to $175 million in EBITDA is also above consensus.
The 2026 EBITDA guidance range implies margins of approximately 13.3% to 14.1% on the revenue midpoint. That is up from 13.1% in full-year 2025, continuing the two-year trend of margin expansion.
The company is not guiding to flat margins. It is guiding to another step up, which means the efficiency gains from 2024 and 2025 are being sustained rather than giving back.
2026 EBITDA guidance of $670M to $710M: Midpoint beats current analyst estimates.
Q1 2026 net sales guidance of 3% to 7% growth: Above consensus at announcement.
The 2026 guide is realistic given Q4. If Q1 lands near the top of the 3% to 7% range, full-year estimates get revised higher.
Action: Q1 lands in the upper half of the 3% to 7% guidance range, add 15% to your position on the day of the print. That tells you the 2026 guide is conservative.
HLF Is Outperforming Consumer Health Peers Since the Earnings Beat
HLF was up 14% on earnings day. The broader consumer health sector was not. That divergence is the relative strength signal worth tracking.
When a stock in a beaten-up category posts a 14% single-day move on fundamentals rather than speculation, it draws a different kind of attention than a news-driven spike.
Institutional money looks at beats like this and compares them to peers who are not delivering.
Direct selling companies broadly have been dealing with distributor attrition. Herbalife is posting 19% distributor growth in North America against that backdrop. The business is gaining ground where peers are losing it.
HLF up 14% on earnings day vs flat broader consumer health sector: Fundamental-driven divergence.
North America distributor growth of 19% vs industry-wide attrition trends: Taking share in a tough environment.
Trades at approximately 9x forward EBITDA: Below the consumer staples sector average of 13x to 15x.
At 9x forward EBITDA, HLF is priced for decline, not recovery. Multiple expansion from 9x to 12x, not EBITDA growth alone, is where the upside comes from.
Action: Compare HLF's 9x forward EBITDA against the 13x to 15x sector average when deciding on position size.
If the growth trajectory holds for two more quarters, the multiple expansion alone drives 30% to 40% upside even without additional EBITDA growth.
Size accordingly.
Trivia: What did the U.S. national debt surpass for the first time in 2025?
The Risks Are Specific, and China Is the Biggest One
China is the most concrete risk in the HLF setup. Q4 China net sales were down 6% in local currency, driven by an 11% volume decline.
Management said recovery is not expected until 2027.
China historically represented a meaningful portion of Herbalife's revenue and profitability, and its continued weakness creates a drag that the rest of the portfolio has to offset.
So far, it has been offset. But if China deteriorates further rather than stabilizing, the offset math gets harder.
The second risk is distributor activation.
New distributors do not all convert into active sellers. If North America activation rates do not follow acquisition rates, the 19% top-of-funnel growth does not translate into revenue.
China down 6% local currency in Q4, recovery not expected until 2027: The drag continues.
New distributor growth is a leading indicator, not a guarantee: Activation rates matter as much as acquisition.
None of these are existential at the current momentum. If Q1 China deteriorates beyond Q4 levels, that is the signal that the drag is worsening, not stabilizing.
Action: Hard stop at $13. China is deteriorating further, plus North America activation rates are disappointing in Q1, which means the thesis breaks. Exit at $13, no waiting.
Final Word: Two Quarters of Growth and a Cleaner Balance Sheet Is the Setup
HLF beat every Q4 guidance metric, posted back-to-back growth quarters, cut leverage to 2.8x, guided 2026 above estimates, and jumped 14% on earnings day. The turnaround is tracking.
Buy at current levels with a $13 stop. Q1 is your next confirmation.
Setup Scorecard
Entry Window: Current levels around $18 to $20. The 14% earnings pop has partially digested. Any pullback to $16 to $17 is a better entry.
Catalyst Watch: Q1 2026 earnings print, China net sales trend, North America distributor activation rates, leverage ratio update.
Upside Setup: Two more quarters of 4% to 6% growth plus multiple expansion from 9x to 12x forward EBITDA drives 30% to 40% upside from current levels.
Downside Cushion: $5 billion revenue base, $333 million operating cash flow, and 13.1% EBITDA margins mean the business does not break on a single weak quarter.
What Moves It Next: Q1 revenue vs the 3% to 7% guidance range and China's trajectory in Q1.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any value names you want me to check out.
Best Regards,
—Noah Zelvis
Undervalued Edge
